NCT04878406 - A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

July 20, 2021

Study Completion Date

July 20, 2021

Conditions

Healthy Volunteers Type 2 Diabetes

Interventions

DRUG

NNC0480-0389

A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.

DRUG

Placebo (NNC0480-0389)

A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.

DRUG

Semaglutide

A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.

DRUG

Placebo (Semaglutide)

A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.

Trial Locations (1)

Novo Nordisk Investigational Site, Fukuoka